These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 24927560)

  • 1. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection.
    Mallajosyula VV; Citron M; Ferrara F; Lu X; Callahan C; Heidecker GJ; Sarma SP; Flynn JA; Temperton NJ; Liang X; Varadarajan R
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):E2514-23. PubMed ID: 24927560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
    Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
    PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.
    Corbett KS; Moin SM; Yassine HM; Cagigi A; Kanekiyo M; Boyoglu-Barnum S; Myers SI; Tsybovsky Y; Wheatley AK; Schramm CA; Gillespie RA; Shi W; Wang L; Zhang Y; Andrews SF; Joyce MG; Crank MC; Douek DC; McDermott AB; Mascola JR; Graham BS; Boyington JC
    mBio; 2019 Feb; 10(1):. PubMed ID: 30808695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions.
    Mittal N; Sengupta N; Malladi SK; Reddy P; Bhat M; Rajmani RS; Sedeyn K; Saelens X; Dutta S; Varadarajan R
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
    Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
    J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conserved stem fragment from H3 influenza hemagglutinin elicits cross-clade neutralizing antibodies through stalk-targeted blocking of conformational change during membrane fusion.
    Gong X; Yin H; Shi Y; Guan S; He X; Yang L; Yu Y; Kuai Z; Jiang C; Kong W; Wang S; Shan Y
    Immunol Lett; 2016 Apr; 172():11-20. PubMed ID: 26875772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.
    Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ
    Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
    Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
    J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen.
    Impagliazzo A; Milder F; Kuipers H; Wagner MV; Zhu X; Hoffman RM; van Meersbergen R; Huizingh J; Wanningen P; Verspuij J; de Man M; Ding Z; Apetri A; Kükrer B; Sneekes-Vriese E; Tomkiewicz D; Laursen NS; Lee PS; Zakrzewska A; Dekking L; Tolboom J; Tettero L; van Meerten S; Yu W; Koudstaal W; Goudsmit J; Ward AB; Meijberg W; Wilson IA; Radošević K
    Science; 2015 Sep; 349(6254):1301-6. PubMed ID: 26303961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
    Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
    Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
    van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
    Front Immunol; 2018; 9():2350. PubMed ID: 30369928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin.
    Mallajosyula VV; Citron M; Lu X; Meulen JT; Varadarajan R; Liang X
    Proteins; 2013 Oct; 81(10):1759-75. PubMed ID: 23625724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligomerization of bacterially expressed H1N1 recombinant hemagglutinin contributes to protection against viral challenge.
    Kuenstling TE; Sambol AR; Hinrichs SH; Larson MA
    Sci Rep; 2018 Aug; 8(1):11856. PubMed ID: 30087372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.
    Bommakanti G; Citron MP; Hepler RW; Callahan C; Heidecker GJ; Najar TA; Lu X; Joyce JG; Shiver JW; Casimiro DR; ter Meulen J; Liang X; Varadarajan R
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13701-6. PubMed ID: 20615991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Pan-H1 Influenza Vaccine.
    Darricarrère N; Pougatcheva S; Duan X; Rudicell RS; Chou TH; DiNapoli J; Ross TM; Alefantis T; Vogel TU; Kleanthous H; Wei CJ; Nabel GJ
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.